Amgen is delighted to announce the launch of the

PCSK9 Competitive Grant Program

, qui permettra aux enquêteurs du monde entier de concourir pour des subventions individuelles allant jusqu'à 200,000 USD for novel research proposals that seek to advance the understanding of PCSK9 and atherosclerosis.

The program is global in reach and is open to proposals from established and junior investigators*.

The deadline for applications is Friday, Peut 11, 2018 (11:59 pm US Pacific Time).

*Junior investigators should be within 5 years of completion of training

 

Catégories : Les cellules souches thérapie

NBScience

contrat organisation de recherche

thérapie de cellules souches